Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the launch of a new awareness campaign, “Play It Forward,” to bring ...

Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to develop new therapies for ...

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Tuesday, April 29th. Analysts expect Sage Therapeutics to post ...

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have added about 7.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $6.99 and traded as ...

CAMBRIDGE, Mass., March 04, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

Biogen proposed acquiring Sage Therapeutics for $7.22 per share; Sage stock has dropped 90% in five years. Sage reorganized in October, cutting 165+ jobs and shifting focus to Zurzuvae for ...

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $13.00. The company’s shares closed ...

Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $17.00. The company’s shares closed yesterday at $10.38.